Immunotherapy for treatment of eyelid squamous cell carcinoma in the horse
The goal of this study is to investigate the safety and efficacy of injectable immunotherapy for treatment of eyelid squamous cell carcinoma in the horse. Horses must be diagnosed with eyelid squamous cell carcinoma to enroll. Horses will have a perilesional injection of immunotherapy performed around the eyelid tumor every four weeks for a total of four injections. The injections are performed with standing sedation and topical anesthetic. Photos with measurements of the tumor will be taken at each recheck to monitor the progress of tumor regression. There is no cost for the injection.
Horses must be found to be systemically healthy with a full physical exam and blood work (complete blood count and serum chemistry). The eyelid tumor must be biopsied in order to confirm the diagnosis of SCC prior to enrollment.
Enrollment ends July 1, 2024